A new report published by Allied Market Research, titled, “Preimplantation Genetics Diagnosis Market: Global Opportunity Analysis and Industry Forecast, 2014–2022”, projects that preimplantation genetic diagnosis market size was $79 million in 2015, and is expected to reach $121 million by 2022, registering a CAGR of 6.14% from 2016 to 2022.

Portland, OR -- (SBWire) -- 12/22/2016 --Preimplantation Genetics Diagnosis Market Report, by Allied Market Research, projects that global market size was $79 million in 2015, and is expected to reach $121 million by 2022, registering a CAGR of 6.14% from 2016 to 2022.

Download Sample at https://www.alliedmarketresearch.com/request-free-sample/1470

The world PGD market is expected to witness notable growth in the coming years owning to the rising prevalence of genetic, hereditary and chromosomal diseases. Moreover, PGD have high chances of conceiving healthy embryos. However, the high costs incurred in the PGD technologies hamper the growth of the market. Moreover, stringent government regulations and ethical concerns also obstruct the growth of the market. In coming years, there would be increase in adoption of PGD worldwide owning to the various applications of PGD for development of healthy embryo. Around 30 to 60% of the human embryos have chromosomal abnormalities. They usually occur in women aged 40 and above. Moreover, chromosomal abnormalities are also seen in working women due to the hectic lifestyle patterns which increase the demand of various diagnostic procedures including PGD.

Summary of the Preimplantation Genetics Diagnosis Market report can be accessed on the website at:
https://www.alliedmarketresearch.com/preimplantation-genetic-diagnosis-market

"People are anxious over potential harmful effects related to chromosomal, genetic, and hereditary issues, leading to infertility-related problems such as PCOS and low sperm count disorders." says Hemali Narkhede, Manager, Healthcare Research at Allied Market Research "PGD helps in preventing inheritance of diseases and thereby eliminating the chances of pregnancy termination," she further added.

Geographically, Europe holds the highest potential to generate major revenue in the global market accounting for about 31.8% share in 2015. While Asia-Pacific is the fastest growing region registering a CAGR of 6.7%.

Key findings of the Preimplantation Genetics Diagnosis Market study:

-Merger and acquisition was the most adopted key strategies during analysis period.

-Pricing of PGD tests is expected to witness a decline with increase in the volume of PGD testing

-Chromosomal Abnormalities test generated the largest share in global PGD market

-HLA Typing and Gender Selection based tests are the two fastest growing segments within Preimplantation Genetics Diagnosis market.

The key market players are F. Hoffmann-La Roche AG, Reprogenetics, LLC, Genea Limited, Illumina, Inc., Laboratory Corporation of America Holdings, Natera, Inc., PerkinElmer, Inc., Quest Diagnostics Incorporated, Genesis Genetics Ltd., and Reproductive Genetics Innovations LLC.